Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanzi Fang
- Development stage
- Preclinical
- Lead developer
- Nanjing University of Chinese Medicine
- Administration
- Oral
01
Overview
Sanzi Fang (SZF) is a Traditional Chinese Medicine (TCM) herbal compound that has been investigated for its potential in the prevention and treatment of colorectal adenoma (CRA). Research, primarily in preclinical mouse models, suggests that SZF exerts its therapeutic effects by modulating the intestinal flora and improving colorectal metabolic profiles. It has been observed to increase beneficial gut bacteria and decrease harmful ones, as well as normalize various colorectal metabolites. This traditional formula is being explored for its ability to prevent the progression of CRA to cancer.
- Other names
- SZF三子方三子方颗粒剂模拟剂Sanzi formula
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on Sanzi Fang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanzi Fang.